NovoCure Limited (NVCR) Financials
NVCR Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2024-03-31 | 1.1 billion | 762.1 million |
2023-12-31 | 1.1 billion | 783.6 million |
2023-09-30 | 1.1 billion | 752.6 million |
2023-06-30 | 1.2 billion | 743.3 million |
NVCR Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2024-03-31 | -43.4 million | 34.1 million |
2023-12-31 | -21.4 million | 17.4 million |
2023-09-30 | -26.6 million | 26.3 million |
2023-06-30 | -29.7 million | 32.7 million |
NVCR Net Income
No data available :(
NVCR Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2024-03-31 | 870.1 million | - | 25.6 million |
2023-12-31 | 910.6 million | - | 27.4 million |
2023-09-30 | 921.2 million | - | 22.1 million |
2023-06-30 | 940.8 million | 567.2 million | 20.3 million |
NVCR Shares Outstanding
NVCR Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2024-03-31 | 11.8 million | 51.6 million | 39.5 million | 55.2 million |
2023-12-31 | 6.8 million | 54.3 million | 39.4 million | 59.2 million |
2023-09-30 | 7.3 million | 53.6 million | 41.9 million | 58.0 million |
2023-06-30 | 6.9 million | 55.4 million | 40.8 million | 58.5 million |
NVCR Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2024-03-31 | 138.5 million | 33.7 million |
2023-12-31 | 133.8 million | 32.6 million |
2023-09-30 | 127.3 million | 32.1 million |
2023-06-30 | 126.1 million | 34.0 million |
NVCR
Price: $14.78
52 week price:
Earnings Per Share: -1.95 USD
P/E Ratio: -8.40
Exchange: NMS
Sector: Healthcare
Industry: Medical Devices
Volume: 542600
Ebitda: -3.9 millionMarket Capitalization: 1.6 billion